Trial Details 114 Total Sites

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

The goal of this study is to evaluate the efficacy and safety of pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib as first-line treatment in participants with advanced clear cell renal cell carcinoma (ccRCC). The primary hypotheses are (1) pembrolizumab plus belzutifan plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to progression-free survival (PFS) and overall survival (OS), in advanced ccRCC participants and (2) pembrolizumab/quavonlimab plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to PFS and OS, in advanced ccRCC participants.

phase

Phase 3

status

Recruiting

enrollment

1431

score

66

start date

2021-04-14

last updated

2022-01-12

biomarkers

N/A

Los Angeles, California
facility
Cedars Sinai Medical Center ( Site 0027)
1 facility
Recruiting
Chicago, Illinois
facility
Rush University Medical Center ( Site 0040)
1 facility
Recruiting
Dallas, Texas
facility
UTSW Medical Center ( Site 0015)
1 facility
Recruiting
Detroit, Michigan
facility
Henry Ford Hospital ( Site 0038)
1 facility
Recruiting
Boston, Massachusetts
facility
Massachusetts General Hospital ( Site 0094)
facility
Beth Israel Deaconess Medical Center ( Site 0089)
+1 more facilities
3 facilities
Recruiting
Portland, Oregon
facility
Oregon Health & Science University ( Site 0071)
1 facility
Recruiting
Nashville, Tennessee
facility
Vanderbilt University Medical Center ( Site 0069)
1 facility
Recruiting
Atlanta, Georgia
facility
Emory University Winship Cancer Institute ( Site 0012)
1 facility
Recruiting
New Orleans, Louisiana
facility
Ochsner Medical Center ( Site 0049)
1 facility
Recruiting
St. Paul, Minnesota
facility
Regions Hospital ( Site 0095)
1 facility
Recruiting
Orlando, Florida
facility
Advent Health Hematology & Oncology ( Site 0003)
1 facility
Recruiting
Fort Wayne, Indiana
facility
Parkview Cancer Institute ( Site 0088)
1 facility
Recruiting